Annovis Bio (ANVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Aug, 2026Executive summary
Special Meeting scheduled for October 2026 will be held virtually, allowing shareholders to vote and ask questions online using a unique control number.
Proxy materials are distributed primarily via the Internet to expedite delivery, reduce costs, and conserve resources, with paper copies available upon request.
The Board unanimously recommends voting in favor of all proposals presented at the meeting.
Voting matters and shareholder proposals
Proposal 1 seeks approval to amend the Certificate of Incorporation to increase authorized Common Stock from 70,000,000 to 140,000,000 and Preferred Stock from 2,000,000 to 10,000,000.
Proposal 2 requests ratification of an amendment to the 2019 Equity Incentive Plan, correcting a prior typographical error and increasing the share reserve to 5,500,000.
Proposal 3 allows adjournment of the Special Meeting if more time is needed to solicit proxies.
Shareholders may also transact other business as may properly come before the meeting.
Board recommends a vote "FOR" all proposals.
Board of directors and corporate governance
Directors and executive officers as a group beneficially own a small percentage of outstanding shares, with detailed ownership disclosed.
Board members and officers are eligible for awards under the Option Plan but receive no special benefit from the proposals beyond potential equity grants.
Procedures for shareholder proposals and director nominations for the 2027 Annual Meeting are outlined, including deadlines and requirements.
Latest events from Annovis Bio
- Alzheimer's phase III top-line data due in March; funding needed to reach NDA and commercialization.ANVS
Investor update - Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026.ANVS
Q2 2026 - Buntanetap shows late-stage efficacy and safety in Alzheimer's and Parkinson's, targeting NDA filings in 2027–2028.ANVS
Investor presentation - Buntanetap delivers cognitive and motor improvements in AD and PD with strong safety and biomarker support.ANVS
Corporate presentation - Q1 net loss rose to $17.6M as R&D spending surged; cash runway extends to Q4 2026.ANVS
Q1 2026 - Virtual annual meeting set for June 17, 2026, with key votes on directors and compensation.ANVS
Proxy filing - Annual meeting to vote on directors, auditor, equity plan, executive pay, and ESG priorities.ANVS
Proxy filing - Buntanetap delivers cognitive and motor benefits in AD and PD, with strong safety and market potential.ANVS
Corporate presentation - Buntanetap demonstrates cognitive and motor benefits in late-stage trials for AD and PD.ANVS
Corporate presentation